Defining a therapeutic range for adalimumab serum concentrations in the management of pediatric noninfectious uveitis, a step towards personalized treatment

Adalimumab is currently considered the most efficacious anti-TNFα agent for childhood noninfectious uveitis (NIU). The objective of this study was to define a therapeutic range for adalimumab trough levels in the treatment of childhood NIU. A retrospective, observational, pilot study of 36 children...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric Rheumatology 2023-12, Vol.21 (1), p.148-148, Article 148
Main Authors: Dehoorne, Jo L, Groth, Helena, Carlé, Emma, De Schrijver, Ilse, Sys, Celine, Delbeke, Patricia, Kreps, Elke O, Renson, Thomas, Bonroy, Carolien
Format: Article
Language:English
Subjects:
Adalimumab
Adalimumab - therapeutic use
Anti-Inflammatory Agents - therapeutic use
Antibodies
Biological products
Care and treatment
Child
Communications equipment
Comparative analysis
Drug dosages
Health aspects
Humans
Inflammation
Inflammatory diseases
Medical imaging
Medical records
Pediatric noninfectious uveitis
Pediatrics
Pilot Projects
Precision Medicine
Retrospective Studies
Rheumatology
Therapeutic drug monitoring
Therapeutic range
Treatment Outcome
Trough levels
Tumor necrosis factor
Uveitis
Uveitis - drug therapy
Visual acuity
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Adalimumab is currently considered the most efficacious anti-TNFα agent for childhood noninfectious uveitis (NIU). The objective of this study was to define a therapeutic range for adalimumab trough levels in the treatment of childhood NIU. A retrospective, observational, pilot study of 36 children with NIU aged 
ISSN:1546-0096
1546-0096
DOI:10.1186/s12969-023-00928-2